Technology giant Philips (NYSE:PHG) won FDA clearance for its MicroDose SI full-field mammography system, which the company hopes to leverage as a platform new mammogram imaging applications.
The system promises reduced radiation dosages in producing high quality images, 5-minute exam times and ergonomic design with curved and warmed breast support.
Philips hopes to enable Single-Shot Spectral Imaging on the system in the future, and is also working on software applications such as Spectral Breast Density Measurement, according to a press release.
"Philips believes that spectral imaging technology will be important in helping clinicians to assess breast density and provide personalized care to women," Lakshmi Gudapakkam, senior vice president & general manager of diagnostic X-ray and mammography solutions, said in prepared remarks. "With the MicroDose SI, Philips contributes to breast cancer screening by delivering the same low dose, high image quality and ergonomics it already offers, while supplying clinicians with spectral-ready technology."